TY - JOUR T1 - Setanaxib as a Potent Hypoxia-specific Therapeutic Agent Against Liver Cancer JF - Anticancer Research JO - Anticancer Res SP - 5071 LP - 5079 DO - 10.21873/anticanres.14510 VL - 40 IS - 9 AU - SATOSHI OWADA AU - HITOSHI ENDO AU - CHISA OKADA AU - KAZUHIRO YOSHIDA AU - YUKARI SHIDA AU - MASAYUKI TATEMICHI Y1 - 2020/09/01 UR - http://ar.iiarjournals.org/content/40/9/5071.abstract N2 - Background/Aim: Liver cancer has extremely poor prognosis. The cancerous tissues contain hypoxic regions, and the available drugs are poorly effective in hypoxic environments. NADPH oxidase 4 (NOX4), producing reactive oxygen species (ROS), may contribute to cancer malignancy under hypoxic conditions. However, its role in liver cancer has not been examined in detail. Our aim was to explore the effects of setanaxib, a recently developed selective NOX4 inhibitor, in liver cancer cells under hypoxic conditions. Materials and Methods: Liver cancer cell lines (HepG2, HLE and Alexander) were treated with hypoxia-mimetic agent cobalt chloride. Cytotoxicity assays, immunoblot analysis and ROS detection assay were performed to detect the effect of setanaxib under hypoxic conditions. Results: Setanaxib exhibited hypoxia-selective cytotoxicity and triggered apoptosis in cancer cells. Moreover, setanaxib caused mitochondrial ROS accumulation under hypoxic conditions. Treatment with antioxidants markedly attenuated setanaxib-induced cytotoxicity and apoptosis under hypoxic conditions. Conclusion: Setanaxib caused mitochondrial ROS accumulation in a hypoxia-selective manner and evoked cancer cell cytotoxicity by inducing apoptosis. Thus, setanaxib has a great potential as a novel anticancer compound under hypoxic conditions. ER -